<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="deo2419" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">DEN Open</journal-id><journal-id journal-id-type="iso-abbrev">DEN Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2692-4609</journal-id><journal-id journal-id-type="publisher-id">DEO2</journal-id><journal-title-group><journal-title>DEN Open</journal-title></journal-title-group><issn pub-type="epub">2692-4609</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39398259</article-id><article-id pub-id-type="pmc">PMC11470743</article-id>
<article-id pub-id-type="doi">10.1002/deo2.419</article-id><article-id pub-id-type="publisher-id">DEO2419</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Lumen&#x02010;apposing metal stents for anastomosis creation throughout the gastrointestinal tract: A large single&#x02010;center experience</article-title><alt-title alt-title-type="left-running-head">G&#x000f6;KCE <sc>et al</sc>.</alt-title></title-group><contrib-group><contrib id="deo2419-cr-0001" contrib-type="author" corresp="yes"><name><surname>G&#x000f6;kce</surname><given-names>Emine</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0000-9840-8650</contrib-id><xref rid="deo2419-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="deo2419-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="deo2419-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>Emine.gokce@ugent.be</email></address></contrib><contrib id="deo2419-cr-0002" contrib-type="author"><name><surname>Devisscher</surname><given-names>Lindsey</given-names></name><xref rid="deo2419-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="deo2419-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="deo2419-cr-0003" contrib-type="author"><name><surname>Rashidian</surname><given-names>Niki</given-names></name><xref rid="deo2419-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="deo2419-cr-0004" contrib-type="author"><name><surname>Palmeri</surname><given-names>Enrico</given-names></name><xref rid="deo2419-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2419-cr-0005" contrib-type="author"><name><surname>Hindryckx</surname><given-names>Pieter</given-names></name><xref rid="deo2419-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="deo2419-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology and Hepatology</named-content>
<institution>Ghent University Hospital</institution>
<city>Ghent</city>
<country country="BE">Belgium</country>
</aff><aff id="deo2419-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Basic and Applied Medical Sciences</named-content>
<institution>Gut&#x02010;Liver Immunopharmacology Unit, Ghent University</institution>
<city>Ghent</city>
<country country="BE">Belgium</country>
</aff><aff id="deo2419-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Liver Research Center Ghent</named-content>
<institution>Ghent University</institution>
<city>Ghent</city>
<country country="BE">Belgium</country>
</aff><aff id="deo2419-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of HPB Surgery and Liver Transplantation</named-content>
<institution>Ghent University Hospital</institution>
<city>Ghent</city>
<country country="BE">Belgium</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Emine G&#x000f6;kce, Department of Gastroenterology and Hepatology, University Hospitals Ghent, University of Ghent, Corneel Heymanslaan 10, 9000 Ghent, Belgium.<break/> Email: <email>Emine.gokce@ugent.be</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>5</volume><issue seq="70">1</issue><issue-id pub-id-type="doi">10.1002/deo2.v5.1</issue-id><elocation-id>e419</elocation-id><history>
<date date-type="rev-recd"><day>26</day><month>7</month><year>2024</year></date>
<date date-type="received"><day>17</day><month>6</month><year>2024</year></date>
<date date-type="accepted"><day>01</day><month>8</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">DEN Open</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DEO2-5-e419.pdf"/><abstract><title>Abstract</title><sec id="deo2419-sec-0010"><title>Objectives</title><p>The introduction of lumen&#x02010;apposing metal stents (LAMSs) has revolutionized the field of therapeutic endoscopic ultrasound. This study aims to evaluate the efficacy and safety of LAMS in creating an endoscopic ultrasound&#x02010;guided anastomosis between two segments of the gastrointestinal (GI) tract.</p></sec><sec id="deo2419-sec-0020"><title>Methods</title><p>Data from all consecutive LAMS procedures for anastomosis creation between two segments of the GI, conducted between October 2019 and February 2024, were retrospectively analyzed for technical success (defined as correct deployment of the LAMS in the target), clinical success (defined as achievement of the intended clinical goal), and adverse events.</p></sec><sec id="deo2419-sec-0030"><title>Results</title><p>A total of 145 LAMS procedures were performed in 136 patients. Indications for LAMS procedures included the need for endoscopic access to or reversal of surgically excluded segments of the GI tract (<italic toggle="yes">n</italic> = 73, 50.3%), and the alleviation of any GI outflow obstruction (<italic toggle="yes">n</italic> = 72, 49.7%). The overall technical and clinical success rates were very high (97.2% and 95.2%, respectively). Adverse events were observed in 20/145 (13.8%) cases, including 11 (7.6%) minor events (AGREE &#x0003c;3) and nine (6.2%) major events (AGREE &#x02265;3). Major events included stent migration (<italic toggle="yes">n</italic> = 1), persisting fistula (<italic toggle="yes">n</italic> = 3), and bleeding (<italic toggle="yes">n</italic> = 4). All adverse events were successfully managed, and there were no procedure&#x02010;related deaths. Loss of LAMS patency occurred in 4/145 (2.8%) cases and could be endoscopically managed in all cases.</p></sec><sec id="deo2419-sec-0040"><title>Conclusions</title><p>The creation of anastomoses with LAMS between two segments of the GI tract appears to be effective and safe, with a low reintervention rate due to loss of LAMS patency.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="deo2419-kwd-0001">EDGE</kwd><kwd id="deo2419-kwd-0002">EDGI</kwd><kwd id="deo2419-kwd-0003">gastric outlet obstruction</kwd><kwd id="deo2419-kwd-0004">lumen&#x02010;apposing metal stent</kwd><kwd id="deo2419-kwd-0005">Roux&#x02010;en&#x02010;Y gastric bypass</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>None</funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="3"/><page-count count="7"/><word-count count="3664"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.02.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="deo2419-sec-0050"><title>INTRODUCTION</title><p>The introduction of lumen&#x02010;apposing metal stents (LAMSs) was an important contribution to the field of therapeutic endoscopic ultrasound (EUS). LAMSs are fully covered, dumbbell&#x02010;shaped stents with a short length and a large internal diameter. While they were developed for drainage of pancreatic fluid collections in 2013, they are now also approved for gallbladder drainage in inoperable patients and biliary drainage in malignant distal biliary obstruction and/or failed endoscopic retrograde cholangiopancreatography (ERCP).<xref rid="deo2419-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="deo2419-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="deo2419-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
</p><p>The use of LAMSs for off&#x02010;label indications has increased significantly and now accounts for about 50% of LAMS use in referral centres<xref rid="deo2419-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>. The unique bi&#x02010;flanged design of LAMSs offers the ability to hold two luminal structures in apposition and therefore allows for anastomosis creation between two adjacent segments of the gastrointestinal (GI) tract. The most commonly created anastomoses are displayed in Figure&#x000a0;<xref rid="deo2419-fig-0001" ref-type="fig">1</xref>).<xref rid="deo2419-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="deo2419-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="deo2419-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="deo2419-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="deo2419-fig-0001"><label>FIGURE 1</label><caption><p>Main types of lumen&#x02010;apposing metal stent anastomosis throughout the gastrointestinal tract. (a) Endoscopic ultrasound&#x02010;guided gastro&#x02010;gastrostomy after Roux&#x02010;en&#x02010;Y gastric bypass. (b) Endoscopic ultrasound&#x02010;guided gastro&#x02010;enterostomy in unaltered anatomy. (c) Endoscopic ultrasound&#x02010;guided duodeno&#x02010;enterostomy after surgical hepaticojejunostomy. (d) Endoscopic ultrasound&#x02010;guided entero&#x02010;enterostomy for afferent loop syndrome after gastrojejunostomy surgery.</p></caption><graphic xlink:href="DEO2-5-e419-g001" position="anchor" id="jats-graphic-1"/></fig><p>Indications for anastomosis creation include: (1) the need for endoscopic access to excluded parts of the GI tract in patients with surgically altered anatomy, (2) alleviation of malignant or benign gastric or enteral outlet obstruction, and (3) a medical need for reversal of a surgical bypass.</p><p>The aim of this study was to evaluate the performance of LAMS for anastomosis creation throughout the GI tract.</p></sec><sec id="deo2419-sec-0060"><title>METHODS</title><p>This study was reviewed and approved by the Ethics Committee of Ghent University Hospital, Belgium (reference number ONZ&#x02010;2024&#x02010;0218).</p><sec id="deo2419-sec-0070"><title>Data collection</title><p>All consecutive patients who underwent EUS&#x02010;guided gastro&#x02010;gastrostomy (EUS&#x02010;GG), gastro&#x02010;enterostomy (EUS&#x02010;GE), or entero&#x02010;enterostomy (EUS&#x02010;EE) between October 2019 and February 2024 at Ghent University Hospital were included. The data were retrieved from a prospectively maintained LAMS database (containing all consecutive patients) and missing data were retrieved from a review of the electronic medical patient records. We divided the patients into two main groups: (1) patients with surgically altered anatomy requiring endoscopic access to (1a) or reversal of (1b) an excluded GI segment and (2) patients with any GI outflow obstruction including malignant gastric outlet obstruction (mGOO; 2a), benign gastric outlet obstruction (bGOO; 2b), candy cane syndrome (2c), or afferent loop syndrome (2d).</p><p>The main outcome data of interest were technical success, clinical success, and adverse events. Technical success was defined as a successful placement of LAMS in the desired position. Clinical success was defined as either successful endoscopic access to the intended excluded gastrointestinal segment in patients with surgically altered anatomy (for subcategory 1a), successful re&#x02010;initiation of oral food intake (for subcategories 2a and 2b), or achievement of the intended therapeutic goal for subcategories 1b, 2c and 2d. Adverse events were classified according to the AGREE criteria and grouped into minor (AGREE I and II) and major adverse events (AGREE IIIa, IIIb, and IV).<xref rid="deo2419-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p></sec><sec id="deo2419-sec-0080"><title>Procedural techniques</title><p>Procedures were performed by highly trained interventional endoscopists with expertise in ERCP and interventional EUS. Only Hot Axios stents (Boston Scientific) were used.</p><sec id="deo2419-sec-0090"><title>EUS&#x02010;guided gastro&#x02010;gastrostomy</title><p>The excluded stomach was identified with EUS from within the stomach pouch. A 19G needle was used to puncture the lumen of the excluded stomach. After fluoroscopic confirmation of the correct position of the needle tip, stained fluid was instilled in the excluded stomach until sufficient space was created for the placement of a 15/10 or 20/10 LAMS. For non&#x02010;urgent indications, endoscopic intubation of the LAMS lumen was performed after an interval of at least 7 days, to allow for fistula tract maturation and thereby reduce the risk of perforation upon dislocation of the LAMS. For urgent indications (e.g., severe cholangiosepsis), endoscopic intubation of the excluded stomach was performed in the same procedure after fixation of the LAMS and balloon dilatation of the LAMS lumen up to 18 mm (Video <xref rid="deo2419-supitem-0002" ref-type="supplementary-material">S1</xref>).</p></sec><sec id="deo2419-sec-0100"><title>EUS&#x02010;guided gastro&#x02010;enterostomy</title><p>Using a therapeutic gastroscope with a working channel of 3.7 mm, a guidewire was placed in the proximal jejunum, right after the angle of Treitz. A 7 Fr nasobiliary drain was positioned over the wire, right distal from the angle of Treitz, and the jejunal segment was filled with indigo carmine&#x02010;stained water. The target loop was identified within the stomach with EUS. When sufficient distension of the jejunal segment was reached, a 20/10 LAMS was placed. The correct position was verified with contrast enterography through the LAMS lumen (Video <xref rid="deo2419-supitem-0003" ref-type="supplementary-material">S2</xref>).</p></sec><sec id="deo2419-sec-0110"><title>EUS&#x02010;guided entero&#x02010;enterostomy</title><p>Through the lumen of the duodenum or the efferent enteral limb, the afferent enteral limb was identified with EUS and punctured with a 19 G needle. The correct position was verified with contrast enterography. The jejunal segment was filled with stained water. When sufficient distension of the jejunal segment was reached, a 15/10 or 20/10 LAMS was placed. The correct position was verified with contrast enterography through the LAMS lumen (Video <xref rid="deo2419-supitem-0004" ref-type="supplementary-material">S3</xref>).</p></sec></sec></sec><sec id="deo2419-sec-0120"><title>RESULTS</title><sec id="deo2419-sec-0130"><title>Patient characteristics</title><p>A total of 145 LAMS were placed in 136 patients (mean age, 60 years; 62.5% women) to create an EUS&#x02010;GG, EUS&#x02010;GE, or EUS&#x02010;EE anastomosis. Baseline patient characteristics per indication are presented in Table&#x000a0;<xref rid="deo2419-tbl-0001" ref-type="table">1</xref>.</p><table-wrap position="float" id="deo2419-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Patient characteristics and procedural details by indication (surgically altered anatomy access/reversal versus gastro&#x02010;intestinal outflow obstruction) and overall.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Indication (<italic toggle="yes">n</italic> = X)</th><th align="left" rowspan="1" colspan="1">Access/reversal surgically altered GI tract (<italic toggle="yes">n</italic> = 73)</th><th align="left" rowspan="1" colspan="1">GI outflow obstruction (<italic toggle="yes">n</italic> = 72)</th><th align="left" rowspan="1" colspan="1">Total (<italic toggle="yes">n</italic> = 145)</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">
<bold>Patient characteristics</bold>
</td></tr><tr><td align="left" rowspan="4" colspan="1">Indications</td><td align="left" rowspan="1" colspan="1">Need for ERCP, <italic toggle="yes">n</italic> = 55 (75.3%)</td><td align="left" rowspan="1" colspan="1">Alleviation benign GOO, <italic toggle="yes">n</italic> = 19 (26.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Need for EUS+FNA, <italic toggle="yes">n</italic> = 5 (6.8%)</td><td align="left" rowspan="1" colspan="1">Alleviation malignant GOO, <italic toggle="yes">n</italic> = 50 (69.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Need for gastroduodenoscopy, <italic toggle="yes">n</italic> = 8 (11.0%)</td><td align="left" rowspan="1" colspan="1">Afferent loop syndrome, <italic toggle="yes">n</italic> = 2 (2.8%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Undo of gastric bypass, <italic toggle="yes">n</italic> = 5 (6.8 %)</td><td align="left" rowspan="1" colspan="1">Candy cane syndrome, <italic toggle="yes">n</italic> = 1 (1.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mean age (years)</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1">Female, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">54 (74.0%)</td><td align="left" rowspan="1" colspan="1">37 (51.4%)</td><td align="left" rowspan="1" colspan="1">91 (62.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">ASA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ASA I, %</td><td align="left" rowspan="1" colspan="1">5.4</td><td align="left" rowspan="1" colspan="1">1.9</td><td align="left" rowspan="1" colspan="1">3.6</td></tr><tr><td align="left" rowspan="1" colspan="1">ASA II, %</td><td align="left" rowspan="1" colspan="1">58.9</td><td align="left" rowspan="1" colspan="1">33.3</td><td align="left" rowspan="1" colspan="1">56.4</td></tr><tr><td align="left" rowspan="1" colspan="1">ASA III, %</td><td align="left" rowspan="1" colspan="1">35.7</td><td align="left" rowspan="1" colspan="1">64.8</td><td align="left" rowspan="1" colspan="1">50.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Underlying malignancy, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">4 (5.5%)</td><td align="left" rowspan="1" colspan="1">51 (70.8%)</td><td align="left" rowspan="1" colspan="1">55 (37.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Non&#x02010;procedure related death, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">5 (6.8%)</td><td align="left" rowspan="1" colspan="1">38 (52.8%)</td><td align="left" rowspan="1" colspan="1">43 (29.7%)</td></tr><tr><td align="left" colspan="4" rowspan="1">
<bold>Procedural details</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Type of LAMS anastomosis</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">EUS&#x02010;GG, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">70 (95.9%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">70 (48.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">EUS&#x02010;GE, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">70 (97.2%)</td><td align="left" rowspan="1" colspan="1">70 (48.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">EUS&#x02010;EE, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">3 (4.1%)</td><td align="left" rowspan="1" colspan="1">2 (2.8%)</td><td align="left" rowspan="1" colspan="1">5 (3.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">LAMS diameter/length, mm</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">15/10</td><td align="left" rowspan="1" colspan="1">6 (8.2%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">6 (4.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">20/10</td><td align="left" rowspan="1" colspan="1">67 (91.8%)</td><td align="left" rowspan="1" colspan="1">72 (100%)</td><td align="left" rowspan="1" colspan="1">139 (95.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">LAMS dilatation, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">27 (37.0%)</td><td align="left" rowspan="1" colspan="1">34 (47.2%)</td><td align="left" rowspan="1" colspan="1">61 (42.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">LAMS fixation, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">36 (49.3%)</td><td align="left" rowspan="1" colspan="1">33 (45.8%)</td><td align="left" rowspan="1" colspan="1">69 (47.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dual session procedure</td><td align="left" rowspan="1" colspan="1">51 (69.9%)</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td></tr><tr><td align="left" rowspan="1" colspan="1">Median duration of LAMS placement, min</td><td align="left" rowspan="1" colspan="1">29 (min 5; max 105; mean 35)</td><td align="left" rowspan="1" colspan="1">36 (min 14; max 122; mean 40)</td><td align="left" rowspan="1" colspan="1">31 (min 5; max 122; mean 35)</td></tr></tbody></table><table-wrap-foot><fn id="deo2419-tbl1-note-0001"><p>Abbreviations: ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasound; EUS&#x02010;EE, endoscopic ultrasound&#x02010;guided entero&#x02010;enterostomy; EUS&#x02010;GE, endoscopic ultrasound&#x02010;guided gastro&#x02010;enterostomy; EUS&#x02010;GG, endoscopic ultrasound&#x02010;guided gastro&#x02010;gastrostomy; FNA, fine needle aspiration, GI, gastrointestinal; GOO, gastric outlet obstruction; LAMS, lumen&#x02010;apposing metal stents</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>The most common indication for anastomosis creation was the need for (temporary) access to an excluded part of the GI tract (68/145; 46.9%). Most patients (65/68; 95.6%) had a previous Roux&#x02010;en&#x02010;Y Gastric Bypass (RYGB) and needed access to the excluded stomach or duodenum. The main reason was the need for EUS&#x02010;directed transgastric ERCP (EDGE procedure; 55/65 cases; 84.6%).</p><p>The second most frequent indication was the alleviation of gastric outlet obstruction (GOO; 69/145; 47.6%), mostly in the setting of malignancy (50/69; 72.5%). Cases of benign gastric outlet obstruction (19/69; 27.5%) were mainly related to chronic pancreatitis with groove components (<italic toggle="yes">N</italic> = 9/19; 47.4%).</p><p>Further, five EUS&#x02010;GG were performed in patients who needed a reversal of RYGB, including one cachectic patient due to metastatic cholangiocarcinoma, three patients with hyperinsulinemic hypoglycemia after RYGB (included in an ongoing in&#x02010;house study), and one patient with therapy&#x02010;resistant small intestinal bacterial overgrowth (SIBO). Lastly, two patients received an LAMS for treatment of an afferent loop syndrome post&#x02010;Whipple surgery, and one patient to manage a candy cane syndrome.</p></sec><sec id="deo2419-sec-0140"><title>Procedural outcomes</title><sec id="deo2419-sec-0150"><title>Technical and clinical success</title><p>The overall technical and clinical success rate was very high (141/145 [97.2%] and 138/145 [95.2%], respectively). Success rates per indication and other procedural outcomes are shown in Table&#x000a0;<xref rid="deo2419-tbl-0002" ref-type="table">2</xref>.</p><table-wrap position="float" id="deo2419-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Procedural outcomes by indication (surgically altered anatomy access/reversal vs. gastro&#x02010;intestinal outflow obstruction).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Indication (<italic toggle="yes">n</italic> = X)</th><th align="left" rowspan="1" colspan="1">Access/reversal surgically altered GI tract (<italic toggle="yes">n</italic> = 73)</th><th align="left" rowspan="1" colspan="1">GI outflow obstruction (<italic toggle="yes">n</italic> = 72)</th><th align="left" rowspan="1" colspan="1">Total (<italic toggle="yes">n</italic> = 145)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Technical success, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">71 (97.3%)</td><td align="left" rowspan="1" colspan="1">70 (97.2%)</td><td align="left" rowspan="1" colspan="1">141 (97.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinical success, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">70 (95.9%)</td><td align="left" rowspan="1" colspan="1">68 (94.4%)</td><td align="left" rowspan="1" colspan="1">138 (95.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse events, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">11 (15.1%)</td><td align="left" rowspan="1" colspan="1">9 (12.5%)</td><td align="left" rowspan="1" colspan="1">20 (13.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Minor (AGREE I, II)</td><td align="left" rowspan="1" colspan="1">7 (9.6%)</td><td align="left" rowspan="1" colspan="1">4 (5.6%)</td><td align="left" rowspan="1" colspan="1">11 (7.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Major (AGREE IIIa, IIIb, IV)</td><td align="left" rowspan="1" colspan="1">4 (5.5%)</td><td align="left" rowspan="1" colspan="1">5 (6.9%)</td><td align="left" rowspan="1" colspan="1">9 (6.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Procedure&#x02010;related deaths (<italic toggle="yes">n</italic>)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Endoscopic LAMS removal, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">53 (72.6%)</td><td align="left" rowspan="1" colspan="1">5 (6.9%)</td><td align="left" rowspan="1" colspan="1">58 (40.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median LAMS dwell time (days)</td><td align="left" rowspan="1" colspan="1">38 (min 7; max 431; mean 61)</td><td align="left" rowspan="1" colspan="1">86 (min 7; max 602; mean 140)</td><td align="left" rowspan="1" colspan="1">67 (min 7; max 602; mean 67)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median follow&#x02010;up, days</td><td align="left" rowspan="1" colspan="1">120 (min 10; max 683; mean 165)</td><td align="left" rowspan="1" colspan="1">134 (min 7; max 602; mean 197)</td><td align="left" rowspan="1" colspan="1">106 (min 7; max 683; mean 165)</td></tr><tr><td align="left" rowspan="1" colspan="1">Loss of patency (all procedures)</td><td align="left" rowspan="1" colspan="1">1 (1.4%)</td><td align="left" rowspan="1" colspan="1">3 (4.2%)</td><td align="left" rowspan="1" colspan="1">4 (2.8%)</td></tr></tbody></table><table-wrap-foot><fn id="deo2419-tbl2-note-0001"><p>Abbreviations: AGREE, adverse events in GI endoscopy; GI, gastrointestinal; LAMS, lumen&#x02010;apposing metal stents.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Four clinical failures were related to technical failure. One patient in the mGOO subgroup could not reinitiate oral intake despite a correct LAMS position. One patient with afferent loop syndrome in whom cholestasis did not improve after LAMS placement needed surgical intervention. The last clinical failure was seen in a patient with cachexia in metastatic cholangiocarcinoma, in whom partial breakdown of her gastric bypass with a LAMS did not improve her nutritional status.</p></sec></sec><sec id="deo2419-sec-0160"><title>Adverse events</title><p>Adverse events were seen in 20/145 cases (13.8%; from which 11 [7.6%] were minor and nine were [6.2%] major) after a median follow&#x02010;up duration of 106 days (range 7&#x02013;683). The adverse event rate, management, and clinical outcome per indication are provided in Table&#x000a0;<xref rid="deo2419-tbl-0003" ref-type="table">3</xref>. With the exception of the persistent fistula, all complications manifested within the 30&#x02010;day post&#x02010;procedural period. There was no procedure&#x02010;related mortality.</p><table-wrap position="float" id="deo2419-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Adverse events by indication (surgically altered anatomy access/reversal versus gastrointestinal outflow obstruction).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Indication</th><th align="left" rowspan="1" colspan="1">Adverse event</th><th align="left" rowspan="1" colspan="1">Complication</th><th align="left" rowspan="1" colspan="1">Needed action</th><th align="left" rowspan="1" colspan="1">Outcome</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Access/reversal surgically altered GI tract (<italic toggle="yes">n</italic> = 11)</td><td align="left" rowspan="1" colspan="1">Minor (<italic toggle="yes">n</italic> = 7)</td><td align="left" rowspan="1" colspan="1">Abdominal pain/nausea/vomiting (<italic toggle="yes">n</italic> = 5)</td><td align="left" rowspan="1" colspan="1">Medication</td><td align="left" rowspan="1" colspan="1">Complete recovery</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Bleeding (<italic toggle="yes">n</italic> = 2)</td><td align="left" rowspan="1" colspan="1">One CT abdomen; one observation</td><td align="left" rowspan="1" colspan="1">Complete recovery</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Major (<italic toggle="yes">n</italic> = 4)</td><td align="left" rowspan="1" colspan="1">Stent migration (<italic toggle="yes">n</italic> = 1)</td><td align="left" rowspan="1" colspan="1">Surgery</td><td align="left" rowspan="1" colspan="1">Complete recovery</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Respiratory desaturation (<italic toggle="yes">n</italic> = 1)</td><td align="left" rowspan="1" colspan="1">Observation PACU</td><td align="left" rowspan="1" colspan="1">Complete recovery</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Persisting fistula (<italic toggle="yes">n</italic> = 2)</td><td align="left" rowspan="1" colspan="1">One surgery; one endoscopy</td><td align="left" rowspan="1" colspan="1">Complete recovery</td></tr><tr><td align="left" rowspan="1" colspan="1">GI outflow obstruction (<italic toggle="yes">n</italic> = 9)</td><td align="left" rowspan="1" colspan="1">Minor (<italic toggle="yes">n</italic> = 4)</td><td align="left" rowspan="1" colspan="1">Abdominal pain/nausea (<italic toggle="yes">n</italic> = 4)</td><td align="left" rowspan="1" colspan="1">Medication</td><td align="left" rowspan="1" colspan="1">Complete recovery</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Major (<italic toggle="yes">n</italic> = 5)</td><td align="left" rowspan="1" colspan="1">Bleeding (<italic toggle="yes">n</italic> = 4)</td><td align="left" rowspan="1" colspan="1">Endoscopy</td><td align="left" rowspan="1" colspan="1">Complete recovery</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Refractory enterocolonic fistula (<italic toggle="yes">n</italic> = 1)</td><td align="left" rowspan="1" colspan="1">Endoscopy</td><td align="left" rowspan="1" colspan="1">Complete recovery</td></tr></tbody></table><table-wrap-foot><fn id="deo2419-tbl3-note-0001"><p>Abbreviation: GI, gastrointestinal; PACU, Post Anesthesia Care Unit.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo2419-sec-0170"><title>Loss of patency</title><p>Indwelling times of LAMSs ranged from 7 to 602 days. Loss of LAMS patency necessitating endoscopic reintervention was observed in 4/145 cases (2.8%) after a median interval of 85 days (range 39&#x02013;592). Patency could be endoscopically restored in all cases.</p></sec></sec><sec id="deo2419-sec-0180"><title>DISCUSSION</title><p>In this large cohort study, LAMSs performed well for anastomosis creation in the GI tract, with a high overall technical (97.2%) and clinical (95.2%) success rates and an acceptable rate of adverse events (13.8%).</p><p>In our study, within the subgroup of patients with RYGB, a LAMS was placed for three indications: EDGE, EUS&#x02010;directed transgastric intervention, and a medical need for the reversal of RYGB.</p><p>EUS&#x02010;directed transgastric intervention&#x000a0;and EDGE have become accepted approaches to gain access to the excluded upper GI tract and deal with pancreaticobiliary disorders in patients with previous gastric bypasses. Our outcome data align with previous reports.<xref rid="deo2419-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="deo2419-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="deo2419-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
</p><p>In almost 70% of cases, EDGE is performed with a dual&#x02010;step approach, to allow for fistula tract maturation and reduce the risk of perforation. The advent of reliable stent fixation devices may change this practice and reduce the burden for the patients.<xref rid="deo2419-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
</p><p>When access to the excluded GI segment is no longer necessary, we remove the LAMS and close the fistula tract, to minimize the risk of a persisting fistula and resulting weight gain. Although the available data suggest a high rate of spontaneous fistula closure,<xref rid="deo2419-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> we experience that most patients demand closure themselves to maximally reduce the potential risk of a persisting fistula and the resulting weight gain. Nevertheless, two persisting fistulas were seen in our cohort, of which one was surgically closed in the referring center.</p><p>Although the numbers are small, we observed promising results of LAMS placement for partial breakdown of a gastric bypass, especially for the indication of hyperinsulinemic hypoglycemia. In this regard, we anticipate that the ongoing LABOR study (NCT05640947) at our unit will provide further insights into effectiveness, safety, and potential indications.</p><p>Furthermore, one patient with therapy&#x02010;resistant SIBO after RYGB experienced significant improvements in diarrhea and bloating and a (desired) weight gain of 9 kg after LAMS placement. Further research is needed to validate these findings.</p><p>Among patients with gastrointestinal outflow obstruction, mGOO was the most common indication for LAMS placement. Both our study and existing literature report high success and acceptable adverse event rates.<xref rid="deo2419-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="deo2419-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="deo2419-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="deo2419-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="deo2419-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="deo2419-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> EUS&#x02010;GE for mGOO is mainly performed in a palliative setting. EUS&#x02010;GE offers superior functional outcomes and a reduced rate of reintervention compared to traditional duodenal stents.<xref rid="deo2419-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="deo2419-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="deo2419-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> In addition, the available literature suggests shorter recovery time, lower adverse event rates, and reduced costs compared to surgical gastroenterostomy.<xref rid="deo2419-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="deo2419-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Three randomized controlled trials are currently ongoing to compare EUS&#x02010;GE with surgical GE: EATING trial (NCT05605327), GOOSE trial (tNCT06071507), and ENDURO trial (ICTRP: NL9592). These studies will possibly confirm EUS&#x02010;GE as the preferred approach to manage malignant gastric outlet obstruction in the palliative setting.</p><p>Our subgroup of patients with bGOO includes cases such as benign duodenal stenosis resulting from caustic injury, ulcers, pancreatitis, etc. Reports from the literature suggest that the placement of LAMS can prevent surgery in the majority of cases.<xref rid="deo2419-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Our results were consistent with the literature. We achieved a technical success rate of 94.7% and a clinical success rate of 89.5% respectively. The European Society of Gastrointestinal Endoscopy guidelines recommend the removal of LAMS when the underlying disease is managed to prevent stent site ulceration. In our cohort, it was possible to remove the LAMS (without closure of the fistula tract) in 4/19 patients (21.1%) after a median interval of 85 days [range 51&#x02013;134], without relapse of GOO. In only 1/19 patients, a loss of patency was observed over time and endoscopically managed. In all other patients, long&#x02010;term indwelling of the LAMS was uneventful. Similar to our own and others&#x02019; experience in patients with mGOO, the patency of the LAMS seems to be unaffected as long as the gastric outlet obstruction persists (and hence, the created EUS&#x02010;GE is still in use).<xref rid="deo2419-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p><p>Nevertheless, further research is essential to precisely define EUS&#x02010;GE's role and safety in bGOO.</p><p>LAMS placement for other outflow obstruction conditions, such as afferent loop syndrome and candy cane syndrome, remains experimental with limited evidence. Nonetheless, it may offer a less invasive alternative for patients who are not fit for surgery.<xref rid="deo2419-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="deo2419-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>
</p><p>In conclusion, our study shows that EUS&#x02010;GG, EUS&#x02010;GE, and EUS&#x02010;EE with LAMSs offer an effective and safe approach to creating anastomoses between gastrointestinal segments. The inclusion of less common indications, the large sample size, and the extended follow&#x02010;up duration enhance the reliability of our findings. Limitations of our study are the retrospective study design without control over confounding factors and the fact that all procedures were performed by highly trained endoscopists in a high&#x02010;volume tertiary center. This might limit the generalization of our findings.</p><p>Data from prospective studies are required to formally approve the indications for LAMS listed in our paper.</p></sec><sec sec-type="COI-statement" id="deo2419-sec-0190"><title>CONFLICT OF INTEREST STATEMENT</title><p>Pieter Hindryckx has received speaker and/or consultancy fees from Boston Scientific, Taewoong Medical, Duomed, and Viatris. Lindsey Devisscher, Niki Rashidian, Enrico Palmeri, and Emine G&#x000f6;kce declare no conflict of interest.</p></sec><sec id="deo2419-sec-0200"><title>ETHICS STATEMENT</title><p>This study was reviewed and approved by the Ethics Committee of Ghent University Hospital, Belgium (reference number ONZ&#x02010;2024&#x02010;0218).</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="deo2419-supitem-0001" position="float" content-type="local-data"><caption><p>TABLE S1 Classification for adverse events in GI endoscopy: the AGREE classification.</p></caption><media xlink:href="DEO2-5-e419-s002.docx"/></supplementary-material><supplementary-material id="deo2419-supitem-0002" position="float" content-type="local-data"><caption><p>VIDEO S1 Endoscopic ultrasound&#x02010;guided gastro&#x02010;gastrostomy (EUS&#x02010;GG).</p></caption><media xlink:href="DEO2-5-e419-s004.mp4" mimetype="video" mime-subtype="mp4"/></supplementary-material><supplementary-material id="deo2419-supitem-0003" position="float" content-type="local-data"><caption><p>VIDEO S2 Endoscopic ultrasound&#x02010;guided gastro&#x02010;enterostomy (EUS&#x02010;GE).</p></caption><media xlink:href="DEO2-5-e419-s003.mp4" mimetype="video" mime-subtype="mp4"/></supplementary-material><supplementary-material id="deo2419-supitem-0004" position="float" content-type="local-data"><caption><p>VIDEO S3 Endoscopic ultrasound&#x02010;guided entero&#x02010;enterostomy (EUS&#x02010;EE).</p></caption><media xlink:href="DEO2-5-e419-s001.mp4" mimetype="video" mime-subtype="mp4"/></supplementary-material></sec></body><back><ref-list id="deo2419-bibl-0001"><title>REFERENCES</title><ref id="deo2419-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="deo2419-cit-0001">
<string-name>
<surname>Hindryckx</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Degroote</surname>
<given-names>H</given-names>
</string-name>. <article-title>Lumen&#x02010;apposing metal stents for approved and off&#x02010;label indications: A single&#x02010;centre experience</article-title>. <source>Surg Endosc</source>
<year>2021</year>; <volume>35</volume>: <fpage>6013</fpage>&#x02013;<lpage>6020</lpage>.<pub-id pub-id-type="pmid">33051767</pub-id>
</mixed-citation></ref><ref id="deo2419-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="deo2419-cit-0002">
<string-name>
<surname>Sharma</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>McCarty</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Chhoda</surname>
<given-names>A</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Alternative uses of lumen apposing metal stents</article-title>. <source>World J Gastroenterol</source>
<year>2020</year>; <volume>26</volume>: <fpage>2715</fpage>&#x02013;<lpage>2728</lpage>.<pub-id pub-id-type="pmid">32550749</pub-id>
</mixed-citation></ref><ref id="deo2419-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="deo2419-cit-0003">
<string-name>
<surname>Stefanovic</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Adler</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Arlt</surname>
<given-names>A</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>International consensus recommendations for safe use of LAMS for on&#x02010; and off&#x02010;label indications using a modified Delphi process</article-title>. <source>Am J Gastroenterol</source>
<year>2024</year>; <volume>119</volume>: <fpage>671</fpage>&#x02013;<lpage>681</lpage>.<pub-id pub-id-type="pmid">37934190</pub-id>
</mixed-citation></ref><ref id="deo2419-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="deo2419-cit-0004">
<string-name>
<surname>Stefanovic</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Degroote</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hindryckx</surname>
<given-names>P</given-names>
</string-name>. <article-title>Reduction of LAMS&#x02010;related adverse events with accumulating experience in a large&#x02010;volume tertiary referral center</article-title>. <source>J Clin Med</source>
<year>2023</year>; <volume>12</volume>: 1037.</mixed-citation></ref><ref id="deo2419-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="deo2419-cit-0005">
<string-name>
<surname>Nass</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Zwager</surname>
<given-names>LW</given-names>
</string-name>, <string-name>
<surname>van der Vlugt</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Novel classification for adverse events in GI endoscopy: The AGREE classification</article-title>. <source>Gastrointest Endosc</source>
<year>2022</year>; <volume>95</volume>: <fpage>1078</fpage>&#x02013;<lpage>1085</lpage>.e8.<pub-id pub-id-type="pmid">34890695</pub-id>
</mixed-citation></ref><ref id="deo2419-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="deo2419-cit-0006">
<string-name>
<surname>Wang</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Ryou</surname>
<given-names>M</given-names>
</string-name>. <article-title>Gastric access temporary for endoscopy (GATE): A proposed algorithm for EUS&#x02010;directed transgastric ERCP in gastric bypass patients</article-title>. <source>Surg Endosc</source>
<year>2019</year>; <volume>33</volume>: <fpage>2024</fpage>&#x02013;<lpage>2033</lpage>.<pub-id pub-id-type="pmid">30805786</pub-id>
</mixed-citation></ref><ref id="deo2419-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="deo2419-cit-0007">
<string-name>
<surname>Kedia</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Tarnasky</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Nieto</surname>
<given-names>J</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>EUS&#x02010;directed transgastric ERCP (EDGE) versus laparoscopy&#x02010;assisted ERCP (LA&#x02010;ERCP) for Roux&#x02010;en&#x02010;Y Gastric Bypass (RYGB) anatomy: A multicenter early comparative experience of clinical outcomes</article-title>. <source>J Clin Gastroenterol</source>
<year>2019</year>; <volume>53</volume>: <fpage>304</fpage>&#x02013;<lpage>308</lpage>.<pub-id pub-id-type="pmid">29668560</pub-id>
</mixed-citation></ref><ref id="deo2419-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="deo2419-cit-0008">
<string-name>
<surname>Wang</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Cortes</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Jirapinyo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Ryou</surname>
<given-names>M</given-names>
</string-name>. <article-title>A comparison of clinical outcomes and cost utility among laparoscopy, enteroscopy, and temporary gastric access&#x02010;assisted ERCP in patients with Roux&#x02010;en&#x02010;Y gastric bypass anatomy</article-title>. <source>Surg Endosc</source>
<year>2021</year>; <volume>35</volume>: <fpage>4469</fpage>&#x02013;<lpage>4477</lpage>.<pub-id pub-id-type="pmid">32886240</pub-id>
</mixed-citation></ref><ref id="deo2419-bib-0009"><label>9</label><mixed-citation publication-type="miscellaneous" id="deo2419-cit-0009">
<string-name>
<surname>Bronswijk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gokce</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Hindryckx</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>van der Merwe</surname>
<given-names>SW</given-names>
</string-name>. <article-title>Single&#x02010;session EUS&#x02010;directed transgastric endoscopic retrograde cholangiopancreatography with a dedicated over&#x02010;the&#x02010;scope fixation device: Feasibility study (with video)</article-title>. Published online: 28 Jul <year>2024</year>; doi.org/10.1111/den.14879.</mixed-citation></ref><ref id="deo2419-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="deo2419-cit-0010">
<string-name>
<surname>James</surname>
<given-names>TW</given-names>
</string-name>, <string-name>
<surname>Baron</surname>
<given-names>TH</given-names>
</string-name>. <article-title>Endoscopic ultrasound&#x02010;directed transgastric ERCP (EDGE): A single&#x02010;center US experience with follow&#x02010;up data on fistula closure</article-title>. <source>Obes Surg</source>
<year>2019</year>; <volume>29</volume>: <fpage>451</fpage>&#x02013;<lpage>456</lpage>.<pub-id pub-id-type="pmid">30302653</pub-id>
</mixed-citation></ref><ref id="deo2419-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="deo2419-cit-0011">
<string-name>
<surname>van der Merwe</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>van Wanrooij</surname>
<given-names>RLJ</given-names>
</string-name>, <string-name>
<surname>Bronswijk</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Therapeutic endoscopic ultrasound: European Society of Gastrointestinal Endoscopy (ESGE) guideline</article-title>. <source>Endoscopy</source>
<year>2022</year>; <volume>54</volume>: <fpage>185</fpage>&#x02013;<lpage>205</lpage>.<pub-id pub-id-type="pmid">34937098</pub-id>
</mixed-citation></ref><ref id="deo2419-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="deo2419-cit-0012">
<string-name>
<surname>Iqbal</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Khara</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>EUS&#x02010;guided gastroenterostomy for the management of gastric outlet obstruction: A systematic review and meta&#x02010;analysis</article-title>. <source>Endosc Ultrasound</source>
<year>2020</year>; <volume>9</volume>: <fpage>16</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">31898587</pub-id>
</mixed-citation></ref><ref id="deo2419-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="deo2419-cit-0013">
<string-name>
<surname>Perez&#x02010;Miranda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tyberg</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Poletto</surname>
<given-names>D</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>EUS&#x02010;guided gastrojejunostomy versus laparoscopic gastrojejunostomy: An international collaborative study</article-title>. <source>J Clin Gastroenterol</source>
<year>2017</year>; <volume>51</volume>: <fpage>896</fpage>&#x02013;<lpage>899</lpage>.<pub-id pub-id-type="pmid">28697151</pub-id>
</mixed-citation></ref><ref id="deo2419-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="deo2419-cit-0014">
<string-name>
<surname>Miller</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Benchaya</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Martel</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>EUS&#x02010;guided gastroenterostomy vs. surgical gastrojejunostomy and enteral stenting for malignant gastric outlet obstruction: A meta&#x02010;analysis</article-title>. <source>Endosc Int Open</source>
<year>2023</year>; <volume>11</volume>: <fpage>E660</fpage>&#x02010;E672.<pub-id pub-id-type="pmid">37593104</pub-id>
</mixed-citation></ref><ref id="deo2419-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="deo2419-cit-0015">
<string-name>
<surname>Carbajo</surname>
<given-names>AY</given-names>
</string-name>, <string-name>
<surname>Kahaleh</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tyberg</surname>
<given-names>A</given-names>
</string-name>. <article-title>Clinical review of EUS&#x02010;guided gastroenterostomy (EUS&#x02010;GE)</article-title>. <source>J Clin Gastroenterol</source>
<year>2020</year>; <volume>54</volume>: <fpage>1</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="deo2419-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="deo2419-cit-0016">
<string-name>
<surname>McCarty</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Garg</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Rustagi</surname>
<given-names>T</given-names>
</string-name>. <article-title>Efficacy and safety of EUS&#x02010;guided gastroenterostomy for benign and malignant gastric outlet obstruction: A systematic review and meta&#x02010;analysis</article-title>. <source>Endosc Int Open</source>
<year>2019</year>; <volume>7</volume>: <elocation-id>E1474</elocation-id>&#x02010;E1482.<pub-id pub-id-type="pmid">31673620</pub-id>
</mixed-citation></ref><ref id="deo2419-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="deo2419-cit-0017">
<string-name>
<surname>Rimba&#x00219;</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lau</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Tripodi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Rizzatti</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Larghi</surname>
<given-names>A</given-names>
</string-name>. <article-title>The role of luminal apposing metal stents on the treatment of malignant and benign gastric outlet obstruction</article-title>. <source>Diagnostics</source>
<year>2023</year>; <volume>13</volume>: 3308.</mixed-citation></ref><ref id="deo2419-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="deo2419-cit-0018">
<string-name>
<surname>James</surname>
<given-names>TW</given-names>
</string-name>, <string-name>
<surname>Greenberg</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Grimm</surname>
<given-names>IS</given-names>
</string-name>, <string-name>
<surname>Baron</surname>
<given-names>TH</given-names>
</string-name>. <article-title>EUS&#x02010;guided gastroenteric anastomosis as a bridge to definitive treatment in benign gastric outlet obstruction</article-title>. <source>Gastrointest Endosc</source>
<year>2020</year>; <volume>91</volume>: <fpage>537</fpage>&#x02013;<lpage>542</lpage>.<pub-id pub-id-type="pmid">31759034</pub-id>
</mixed-citation></ref><ref id="deo2419-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="deo2419-cit-0019">
<string-name>
<surname>Kastelijn</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Moons</surname>
<given-names>LMG</given-names>
</string-name>, <string-name>
<surname>Garcia&#x02010;Alonso</surname>
<given-names>FJ</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Patency of endoscopic ultrasound&#x02010;guided gastroenterostomy in the treatment of malignant gastric outlet obstruction</article-title>. <source>Endosc Int Open</source>
<year>2020</year>; <volume>8</volume>: <elocation-id>E1194&#x02212;</elocation-id>E1201.<pub-id pub-id-type="pmid">32904815</pub-id>
</mixed-citation></ref><ref id="deo2419-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="deo2419-cit-0020">
<string-name>
<surname>Ouazzani</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gasmi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gonzalez</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Barthet</surname>
<given-names>M</given-names>
</string-name>. <article-title>Candy cane syndrome: A new endoscopic treatment for this underappreciated surgical complication</article-title>. <source>Endoscopy</source>
<year>2023</year>; <volume>55</volume>: <fpage>E414</fpage>&#x02013;<lpage>E415</lpage>.<pub-id pub-id-type="pmid">36758628</pub-id>
</mixed-citation></ref><ref id="deo2419-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="deo2419-cit-0021">
<string-name>
<surname>Brewer Gutierrez</surname>
<given-names>OI</given-names>
</string-name>, <string-name>
<surname>Irani</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Ngamruengphong</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Endoscopic ultrasound&#x02010;guided entero&#x02010;enterostomy for the treatment of afferent loop syndrome: A multicenter experience</article-title>. <source>Endoscopy</source>
<year>2018</year>; <volume>50</volume>: <fpage>891</fpage>&#x02013;<lpage>895</lpage>.<pub-id pub-id-type="pmid">29499577</pub-id>
</mixed-citation></ref></ref-list></back></article>